Author(s):
S. Dhanalakshmi, N. Harikrishnan, N. Janani, P. Shakthi priya, M. Srinivasan, A. Karthikeyan, A. Anishkumar, R. Harinathan, N. Srinivasan
Email(s):
dhanadinesh2011@gmail.com
DOI:
10.52711/0974-360X.2021.00693 
Address:
S. Dhanalakshmi1*, N. Harikrishnan2, N. Janani3, P. Shakthi priya4, M. Srinivasan5, A. Karthikeyan6, A. Anishkumar7, R. Harinathan8, N. Srinivasan9
1Department of Pharmacognosy, Faculty of Pharmacy, Dr. M.G.R Educational and Research Institute (Deemed to be Univ), Velappanchavadi, Chennai – 600077.
2Department of Pharmaceutical Chemistry and Analysis, Faculty of Pharmacy, Dr. M.G.R Educational and Research Institute (Deemed to be Univ), Velappanchavadi, Chennai – 600077.
3-8Pharma Buddy, Faculty of Pharmacy, Dr. M.G.R Educational and Research Institute (Deemed to be Univ), Velappanchavadi, Chennai – 600 077.
9Department of Pharmacy, Faculty of Engineering and Technology, Annamalai University, Annamalai Nagar, Chidambaram.
*Corresponding Author
Published In:
Volume - 14,
Issue - 7,
Year - 2021
ABSTRACT:
Endometrial carcinoma (EC) is the most common gynecologic malignancy in the United States. Prognosis depends on patient age, histological grade, depth of myometrial invasion and/or cervical invasion, and the presence of lymph node metastases. Although EC is staged surgically according to the International Federation of Gynecology and Obstetrics (FIGO) system, preoperative imaging can assist in optimal treatment planning. Several imaging techniques such as transvaginal ultrasonography (TVUS), computed tomography (CT), and magnetic resonance imaging (MRI) have been used as diagnostic tools for preoperative staging of EC. Recently, positron emission tomography (PET), PET/CT, and PET/MRI have also been used in staging these patients. In this article, we review stageing, risk factors, value of imaging in diagnosis, recent research on treatment planning, and detection of recurrent disease in patients with EC.
Cite this article:
S. Dhanalakshmi, N. Harikrishnan, N. Janani, P. Shakthi priya, M. Srinivasan, A. Karthikeyan, A. Anishkumar, R. Harinathan, N. Srinivasan. The Overview: Recent Studies on Endometrial Cancer. Research Journal of Pharmacy and Technology. 2021; 14(7):3998-2. doi: 10.52711/0974-360X.2021.00693
Cite(Electronic):
S. Dhanalakshmi, N. Harikrishnan, N. Janani, P. Shakthi priya, M. Srinivasan, A. Karthikeyan, A. Anishkumar, R. Harinathan, N. Srinivasan. The Overview: Recent Studies on Endometrial Cancer. Research Journal of Pharmacy and Technology. 2021; 14(7):3998-2. doi: 10.52711/0974-360X.2021.00693 Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-7-90
REFERENCE:
1. Allott EH., et al., Performance of Three Biomarker Immunohistochemistry for Intrinsic Breast Cancer Subtyping in the AMBER Consortium. Cancer Epidemiology, Biomarkers and Prevention, 2016; 25: Pg.no 470-478.
2. Analele et al., Endometrium cancer and ts risk factor. MIHAI-VLAD, Gynecol Oncolology 145, (5), 2017, pg.no: 258-272.
3. American Cancer Society: Cancer Facts and Figures 2019. Atlanta, Ga: American Cancer Society, 2019. Last accessed December 12, 2019, Pg.no: 528 -536
4. Ward KK et al., Cardiovascular disease is the leading cause of death among endometrial cancer patients. Gynecol Oncol 126 (2):2012, pg.no: 176-179.
5. Beral et al., Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365 (9470): 2005, Pg.no:1543-1551.
6. Endometrial Cancer: a guide for patients - Information based on ESMO Clinical Practice Guidelines – v.2012.1Pg.no: 561-570.
7. Anderson GL, et al., Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291 (14): 2004, pg.no: 1701-12.
8. Furness S et al., Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev (2): CD000402, 2009.
9. Andreano A. et al., MR diffusion imaging for preoperative staging of myometrial invasion in patients with endometrial cancer: a systematic review and meta-analysis. Eur Radiol. 2014 Jun; 24(6): 2014, 1327-38.
10. Bae HS et al., Postoperative lower extremity edema in patients with primary endometrial cancer. Ann Surg Oncol. 2016; 23(1): 186-95
11. DeMichele A, et al., Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study. J Clin Oncol 26 (25): 2008, Pg.no: 4151-9.
12. Beesley VL., et al., Incidence, risk factors and estimates of a woman's risk of developing secondary lower limb 16 lymphedema and lymphedema-specific supportive care needs in women treated for endometrial cancer. Gynecol Oncology. 2015; 136(1): pg.no: 87-93.
13. Aune D, et al., Anthropometric factors and endometrial cancer risk: a systematic review and dose-response meta-analysis of prospective studies. Ann Oncology 26 (8):2015, pg.no: 1635-48.
14. Binder PS, et al., Update on prognostic markers for endometrial cancer. Womens Health (Lond Engl) 10 (3): 277-88, 2014.
15. Pecorelli S: Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstetology 105 (2):2009, pg.no: 103-104.
16. Martin-Hirsch PP et al., Adjuvant progestogens for endometrial cancer. Cochrane Database Syst Rev (6): CD001040, 2011.
17. Fader AN, et al., Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. Cancer 115 (10): 2009, Pg.no: 2119-27.
18. Orezzoli JP et al., Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion. Gynecol Oncol 113 (3): 2009, pg.no: 316-23.
19. Huh WK et al., Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy. Gynecol Oncology 91 (3): 2003, pg.no 470-5.
20. Janda M, et al., Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer (LACE): a randomised trial. Lancet Oncology 11 (8): 2010, pg.no: 772-80.